PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 31829

Cumulative dose-response curves for early evaluation of bronchodilator drugs.

S Larsson·N Svedmyr
View original source ↗Export metadata ↓

Abstract

SM 220, a new beta-receptor agonist, was compared with terbutaline by construction of dose response curves for FEV1, heart rate and blood pressure. The pharmacological profile of SM 220 after preclinical studies was that of a potent and highly selective bronchodilator. In this study the beta2 selectivity of SM 220 was poorer than that of terbutaline. The importance of commencing clinical evaluation of bronchodilators with a dose-response test is stressed.

Explore related subjects

Adrenergic beta-AgonistsAdultBlood PressureBronchodilator AgentsCatecholaminesClinical Trials as TopicDose-Response Relationship, DrugDouble-Blind MethodEthanolaminesEvaluation Studies as TopicFemaleForced Expiratory VolumeHeart RateHumansLung Diseases, ObstructiveMaleMiddle AgedTerbutalineClinical TrialComparative StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Larsson, N Svedmyr. 1978. Cumulative dose-response curves for early evaluation of bronchodilator drugs.. https://pubmed.ncbi.nlm.nih.gov/31829/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1979

In vitro modulation of CNS beta-receptor number by antidepressants and beta-agonists.

In vitro incubation of rat cerebral cortex slices with antidepressant drugs reduced beta-adrenergic receptor binding of 3H-dihydroalprenolol by 30%. The decrease was maximum after 60 min, and was reversible after 120 min. (-)-Isoproterenol incubation caused a rapid and reversible loss (60%) of beta-receptor binding. Both effects were due to a decrease in beta-receptor sites. In vitro beta-receptor subsensitivity due to desipramine and isoproterenol was non-additive. The observed reversible loss of beta-receptor sites may be an initial phase of the beta-receptor down-regulation by antidepressants seen in vivo.

Adrenergic beta-Agonists↗